Vuignier Yann, Wojtusciszyn Anne, Kosinski Christophe
Service d'endocrinologie, diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Rev Med Suisse. 2022 Jun 1;18(784):1110-1114. doi: 10.53738/REVMED.2022.18.784.1110.
Treatment combining long-acting and short-acting insulins is essential for people with type 1 diabetes, but may become also compulsory in other forms of diabetes in case of insulinopenia. The purpose of short-acting insulins is to mimic physiological insulin secretion in response to carbohydrate intake at meals. There is a delay between the injection and its action, sometimes limiting their use and effectiveness. Ultra-rapid insulins have been developed to more closely approximate the expected insulin response to a meal, through faster absorption. They do not improve diabetes control but allow more flexibility with mealtime injections. These new analogues are also an attractive alternative for use in insulin pumps.
对于1型糖尿病患者而言,长效胰岛素与短效胰岛素联合治疗至关重要,而在胰岛素分泌不足的其他糖尿病类型中,这种联合治疗也可能成为必要手段。短效胰岛素的作用是模拟进餐后机体对碳水化合物摄入所产生的生理性胰岛素分泌。注射与起效之间存在延迟,这有时会限制其使用及效果。超短效胰岛素已被研发出来,通过更快的吸收,更接近进餐时预期的胰岛素反应。它们虽不能改善糖尿病控制情况,但能在进餐时注射方面提供更大的灵活性。这些新型类似物也是用于胰岛素泵的一种有吸引力的选择。